Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the third tranche of its 2025 Corporate Bonds in the PRC, raising RMB3 billion with a coupon rate of 1.82% per annum. The proceeds from this issuance will be utilized to repay interest-bearing debt, which could potentially strengthen the company’s financial position and enhance its operational capabilities.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is a significant player in the Chinese market, leveraging its extensive network and resources to maintain a competitive edge.
Average Trading Volume: 12,514,624
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.55B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.